The Responsible Person: A Comprehensive Review (2026) 

The Responsible Person – Overseer of Good Distribution Practice

The Responsible Person (RP) occupies a pivotal role within a wholesale distribution organisation.
While the Wholesale Distribution Authorisation (WDA) Licence Holder carries overall legal accountability, the RP is the individual entrusted with ensuring that wholesale distribution activities are conducted in compliance with Good Distribution Practice (GDP) on a day-to-day basis. The RP acts as the operational guardian of quality, integrity, and regulatory compliance across the medicines supply chain.

The responsibilities of the RP are defined through a combination of UK legislation, primarily the Human Medicines Regulations 2012 and the operational expectations set out in the EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01) as adopted by the UK. Together, these establish the RP as a role requiring authority, competence, independence, and continual oversight.

Legal basis of the RP role

The Human Medicines Regulations 2012 require wholesale distributors to operate in accordance with GDP and to ensure that their activities are properly supervised.
The Regulations explicitly link compliance with GDP to the conditions of the WDA:

“The Licence Holder must comply with the guidelines on good distribution practice.”
(Human Medicines Regulations 2012, regulation 18)

While the regulation addresses the Licence Holder, GDP guidelines clarify how compliance is achieved in practice, namely through the appointment of a designated individual responsible for GDP compliance.
The EU GDP Guidelines state:

“The management of the distributor should designate a person responsible for GDP compliance.”
(EU GDP, Chapter 2 – Personnel)

This requirement identifies the RP as the focal point for ensuring that GDP is embedded, maintained, and effectively applied throughout wholesale operations.

Authority, independence and organisational position

For the RP to be effective, they must have sufficient authority within the organisation.
GDP Guidelines emphasise that responsibility must be matched with decision-making power:

“The person responsible should have defined authority and responsibility for ensuring that a quality system is implemented and maintained.”
(EU GDP, Chapter 2 – Personnel)

This means the RP must be able to influence operational decisions, stop distribution where GDP compliance is at risk, and escalate issues to senior management without obstruction. The RP role is therefore not administrative but managerial and professional, requiring independence from purely commercial pressures.

Oversight of the Quality Management System (QMS)

One of the RP’s central responsibilities is oversight of the Quality Management System.
GDP establishes quality as a structured and documented system:

“A quality system should be developed, implemented and maintained.”
(EU GDP, Chapter 1 – Quality Management)

The RP is responsible for ensuring that this system is not only in place but effective. This includes approving and maintaining SOPs, ensuring deviations and non-conformances are investigated, and verifying that corrective and preventive actions (CAPA) are implemented and effective.

The RP must also ensure that quality objectives align with GDP’s overarching purpose and are reflective of the authorised licensable activities:

“Compliance with these Guidelines will ensure control of the distribution chain and consequently maintain the quality and the integrity of medicinal products.”
(EU GDP, Chapter 1 – Quality Management)

Personnel training and competence

The RP has a direct responsibility for ensuring that personnel involved in wholesale distribution are adequately trained and competent.

GDP states clearly:

“Personnel should be trained in the requirements of GDP.”
(EU GDP, Chapter 2 – Personnel)

Training must be in line with a documented training schedule, and be:

• • Appropriate to role outlined within the job description
  • Communicated effectively
  • Regularly updated
  • Fully documented to show what training has been undertaken and when

The RP must ensure that staff understand GDP principles, relevant SOPs, and the impact of their actions on product quality and patient safety.

This responsibility extends beyond initial induction training and includes ongoing assessment of employee competence, refresher training, and targeted training following incidents or procedural changes to ensure compliance with GDP activities.

Control of premises and storage conditions

Although the WDA Licence Holder is responsible for the suitability of premises, the RP is responsible for ensuring that GDP requirements are applied in practice.

The Regulations require consideration of:

“…the premises in which medicinal products…will be stored” and “…the equipment which is available for storing medicinal products on those premises.”
(Human Medicines Regulations 2012, Schedule 2)

GDP reinforces this operational responsibility:

“Medicinal products should be stored under conditions which assure that their quality is maintained.”
(EU GDP, Chapter 3 – Premises and Equipment)

The RP must ensure that storage conditions are defined, monitored, and documented, that temperature excursions are investigated, and that appropriate segregation exists for quarantined, returned, or recalled stock.

Qualification and supply chain oversight

The RP plays a critical role in ensuring that trade of medicinal products is only conducted with authorised and approved suppliers and customers.
GDP requires that:

“Suppliers …customers… of medicinal products should be approved and authorised.”
(EU GDP, Chapter 5 – Operations)

The RP typically oversees or approves the qualification processes for suppliers and customers, ensuring that due diligence is performed, entities are authorised to trade. Performance is monitored through a review of transactions, deviation trend analysis and periodic requalification. Where risks are identified, the RP must ensure that appropriate and measured controls or restrictions are applied.

This responsibility is essential to preventing the misuse of medicines and falsified medicines from entering the supply chain.

Documentation and traceability

Robust documentation underpins GDP compliance, and the RP is responsible for ensuring that records support full traceability.
GDP specifies:

“Documentation comprises of all written procedures, instructions, contracts, records and data, in paper or electronic form. Documentation should be readily available/ retrievable.”
(EU GDP, Chapter 4 – Documentation)

The Human Medicines Regulations further require traceability for certain medicinal products, stating that systems must ensure:

“…the medicinal product and its starting materials can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery.”
(Human Medicines Regulations 2012, regulation 48)

The RP must ensure that documentation systems are accurate, secure, and are readily retrievable for inspection by competent authorities.

Transportation and outsourced activities

Transportation is a critical risk point in distribution.
GDP states:

“Medicinal products should be transported in such a way that their quality is maintained.”
(EU GDP, Chapter 9 – Transportation)

The RP is responsible for ensuring that transport arrangements, including outsourced logistics providers, operate in compliance with GDP. This includes auditing transport providers, reviewing contracts, and ensuring that temperature control, security, and documentation requirements are met.

Outsourcing does not remove responsibility; the RP must maintain oversight of third-party activities which have potential to affect product quality.

Management of returns, recalls and suspected falsification

GDP assigns significant responsibility to the RP in managing non-standard situations.
Returned products must be carefully assessed:

“An assessment of returned medicinal products should be performed before any approval for resale.”
(EU GDP, Chapter 6 – Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls)

The RP must ensure that assessments are documented and that products are only returned to saleable stock by the RP when the history, provenance, quality and integrity of the medicinal product can be assured. In cases of suspected falsification, the RP must ensure immediate segregation and appropriate escalation (e.g. Yellow Card reporting).

The RP also plays a central role in recall activities, ensuring traceability, timely communication, and effective execution of recall procedures.

Self-inspections and continual improvement

To maintain compliance, GDP requires systematic self-inspection:

“Self-inspections should be conducted in order to monitor implementation and compliance with GDP principles and to propose corrective measures.”
(EU GDP, Chapter 8 – Self-Inspections)

The RP is typically responsible for planning, conducting, or overseeing self-inspections, reviewing findings, and ensuring corrective actions are implemented and verified for effectiveness. This reinforces the RP’s role in driving continual improvement rather than reactive compliance.

Interface with competent authorities

The RP is often the primary point of contact with regulatory authorities during inspections. They must be able to demonstrate GDP compliance, explain quality systems, and provide access to records. Cooperation with inspections and prompt resolution of deficiencies are integral to maintaining the WDA licence under the Human Medicines Regulations 2012 (as amended).

Conclusion

The RP role is central to the safe and lawful distribution of medicinal products.
While the WDA Licence Holder carries overarching legal responsibility, the RP ensures that GDP compliance is achieved in practice every day, across every licensable activity.

As GDP makes clear, a designated individual must be responsible for compliance (EU GDP, Chapter 2), and as national law requires, wholesale activities must comply with GDP (HMR 2012, regulation 18). Together, these obligations define the RP as the operational custodian of quality, integrity, and patient safety within the wholesale medicines supply chain.